Medicinal chemistry of adenosine, P2Y and P2X receptors.
Bethesda, United States. In Neuropharmacology, Jan 2016
Some of these compounds, including A1 and A3 AR agonists, P2Y1R and P2Y12R antagonists, and P2X3, P2X4 and P2X7 antagonists, are potentially of clinical use in treatment of disorders of the nervous system, such as chronic pain, neurodegeneration and brain injury.
Pyroptosis: Caspase-11 Unlocks the Gates of Death.
Lausanne, Switzerland. In Immunity, Dec 2015
In this issue of Immunity, Núñez and colleagues report that caspase-11 cleaves the transmembrane channel pannexin-1, causing an efflux of cellular ATP that promotes a P2X7 receptor-dependent pyroptosis.
Purinergic signalling in brain ischemia.
Florence, Italy. In Neuropharmacology, Dec 2015
Among P2X receptors most evidence indicate that P2X7 receptor contribute to the damage induced by the ischemic insult due to intracellular Ca(2+) loading in central cells and facilitation of glutamate release.
ATPergic signalling during seizures and epilepsy.
Dublin, Ireland. In Neuropharmacology, Dec 2015
To date, work showing the functional contribution of P2 receptors has been mainly performed in animal models of acute seizures, in particular, by targeting the ionotropic P2X7 receptor subtype.
Purinergic receptors in psychiatric disorders.
Leipzig, Germany. In Neuropharmacology, Nov 2015
Among the P2 receptor family, in particular P2X7 and P2Y1 receptors were related to disturbances in major depression and schizophrenia, respectively.
Purinergic contribution to amyotrophic lateral sclerosis.
Roma, Italy. In Neuropharmacology, Nov 2015
In particular, here we recapitulate very early results about P2X4, P2X7 and P2Y6 receptor expression in tissues from ALS animal and cell models and patients, and more recent achievements about purinergic signalling mainly performed in vitro in microglia and lately in astrocytes and motoneurons.